TW202342477A - 二醯基甘油激酶(DGK) α抑制劑及其用途 - Google Patents

二醯基甘油激酶(DGK) α抑制劑及其用途 Download PDF

Info

Publication number
TW202342477A
TW202342477A TW112107272A TW112107272A TW202342477A TW 202342477 A TW202342477 A TW 202342477A TW 112107272 A TW112107272 A TW 112107272A TW 112107272 A TW112107272 A TW 112107272A TW 202342477 A TW202342477 A TW 202342477A
Authority
TW
Taiwan
Prior art keywords
alkyl
heterocycloalkyl
cycloalkyl
heteroaryl
compound
Prior art date
Application number
TW112107272A
Other languages
English (en)
Chinese (zh)
Inventor
陸洪福
余華星
丁曉
任峰
Original Assignee
香港商英矽智能科技知識產權有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 香港商英矽智能科技知識產權有限公司 filed Critical 香港商英矽智能科技知識產權有限公司
Publication of TW202342477A publication Critical patent/TW202342477A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112107272A 2022-03-01 2023-03-01 二醯基甘油激酶(DGK) α抑制劑及其用途 TW202342477A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN2022078653 2022-03-01
WOPCT/CN2022/078653 2022-03-01
CN2022091497 2022-05-07
WOPCT/CN2022/091497 2022-05-07
WOPCT/CN2022/127020 2022-10-24
CN2022127020 2022-10-24
CN2023071857 2023-01-12
WOPCT/CN2023/071857 2023-01-12

Publications (1)

Publication Number Publication Date
TW202342477A true TW202342477A (zh) 2023-11-01

Family

ID=87883011

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112107272A TW202342477A (zh) 2022-03-01 2023-03-01 二醯基甘油激酶(DGK) α抑制劑及其用途

Country Status (12)

Country Link
US (2) US20240051958A1 (enExample)
EP (1) EP4486741A4 (enExample)
JP (1) JP2025508971A (enExample)
KR (1) KR20240156394A (enExample)
CN (1) CN118871438A (enExample)
AR (1) AR128669A1 (enExample)
AU (1) AU2023227010A1 (enExample)
CA (1) CA3244501A1 (enExample)
IL (1) IL315015A (enExample)
MX (1) MX2024010648A (enExample)
TW (1) TW202342477A (enExample)
WO (1) WO2023165504A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315015A (en) 2022-03-01 2024-10-01 Insilico Medicine Ip Ltd Diacylglycerol kinase (DGK) alpha inhibitors and their uses
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合
CN122094689A (zh) * 2023-09-04 2026-05-26 英矽智能科技知识产权有限公司 二酰甘油激酶(DGK)α抑制剂与其他疗法的组合治疗

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
AU2004220176A1 (en) 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
WO2011075747A1 (en) 2009-12-18 2011-06-23 Glaxosmithkline Llc Therapeutic compounds
US10376504B2 (en) * 2015-07-29 2019-08-13 Merck, Sharp & Dohme Corp. Substituted quinolinones as PDE9 inhibitors
CN111406050B (zh) * 2018-01-17 2023-02-03 厦门宝太生物科技股份有限公司 吲哚胺2,3-双加氧酶抑制剂及其用途
SG11202012973RA (en) 2018-06-27 2021-01-28 Bristol Myers Squibb Co Naphthyridinone compounds useful as t cell activators
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
MA56444A (fr) 2019-07-04 2022-05-11 Lead Pharma Holding Bv MODULATEURS DU RÉCEPTEUR ALPHA DES OESTROGÈNES (ERRalpha)
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
HRP20240237T1 (hr) 2019-10-18 2024-05-10 Lead Pharma Holding B.V. Modulatori receptora alfa (err-alfa) povezanih s estrogenom
US12478621B2 (en) * 2019-11-28 2025-11-25 Deutsches Krebsforschungszentrum Substituted aminoquinolones as dgkalpha inhibitors for immune activation
WO2021105115A1 (en) 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
EP4065584A1 (en) 2019-11-28 2022-10-05 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
WO2021127554A1 (en) 2019-12-19 2021-06-24 Bristol-Myers Squibb Company Combinations of dgk inhibitors and checkpoint antagonists
CA3162979A1 (en) 2019-12-23 2021-07-01 Upender Velaparthi Substituted piperazine derivatives useful as t cell activators
MX2022007369A (es) 2019-12-23 2022-07-12 Bristol Myers Squibb Co Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t.
IL294148A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted quinazolinyl compounds are useful as t-cell activators
JP7677976B2 (ja) * 2019-12-23 2025-05-15 ブリストル－マイヤーズ スクイブ カンパニー Ｔ細胞アクティベーターとして有用な置換ヘテロアリール化合物
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
AU2021400725A1 (en) 2020-12-16 2023-08-03 Gossamer Bio Services, Inc. Compounds useful as t cell activators
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
CA3228862A1 (en) 2021-08-03 2023-02-09 Beigene, Ltd. Pyrazolopyridinone compounds
WO2023165528A1 (en) 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
EP4486745A4 (en) 2022-03-01 2026-03-11 Insilico Medicine Ip Ltd Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses
WO2023165525A1 (en) 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
IL315015A (en) 2022-03-01 2024-10-01 Insilico Medicine Ip Ltd Diacylglycerol kinase (DGK) alpha inhibitors and their uses
JP2025510945A (ja) 2022-03-31 2025-04-15 インベンティスバイオ カンパニー リミテッド キナーゼ阻害剤、その製造方法および用途
WO2023184327A1 (en) 2022-03-31 2023-10-05 InventisBio Co., Ltd. Kinase inhibitors, preparation methods and uses thereof

Also Published As

Publication number Publication date
EP4486741A1 (en) 2025-01-08
IL315015A (en) 2024-10-01
WO2023165504A1 (en) 2023-09-07
KR20240156394A (ko) 2024-10-29
EP4486741A4 (en) 2026-04-08
US12077538B2 (en) 2024-09-03
CA3244501A1 (en) 2023-09-07
US20240051958A1 (en) 2024-02-15
AU2023227010A1 (en) 2024-09-12
JP2025508971A (ja) 2025-04-10
US20240116935A1 (en) 2024-04-11
CN118871438A (zh) 2024-10-29
MX2024010648A (es) 2024-11-08
AR128669A1 (es) 2024-06-05

Similar Documents

Publication Publication Date Title
AU2020214404B2 (en) Immunomodulators, compositions and methods thereof
TWI912127B (zh) KRas G12D抑制劑
CA2971640C (en) Cot modulators and methods of use thereof
CA3226720A1 (en) Kras g12d inhibitors and uses thereof
TWI627174B (zh) Ｐ２ｘ７調控劑
US12077538B2 (en) Diacylglycerol kinase (DGK) alpha inhibitors and uses thereof
AU2013344049A1 (en) ALK kinase inhibitors
TW202342478A (zh) 二醯基甘油激酶（ＤＧＫ）α抑制劑及其用途
JP2018513150A (ja) チロシンキナーゼ阻害剤およびそれを含む医薬組成物
WO2023165525A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
TWI826535B (zh) 環狀二核苷酸類似物、其藥物組合物及應用
WO2023165528A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
CN120535527A (zh) 一类含氮稠环类化合物、制备方法和用途
WO2024149389A1 (zh) 取代桥环类抑制剂及其制备方法和应用
KR20240093606A (ko) 치환된 1H-피라졸로[4,3-c] 퀴놀린, 이의 제조 방법 및 용도
US20160297824A1 (en) Imidazo-fused heterocycles and uses thereof
CN121941684A (zh) Cbl-b抑制剂及其使用方法
KR20250073137A (ko) Egfr 억제제 및 그의 용도
AU2023224815A1 (en) Compound as fak inhibitor and use thereof
CN117729921A (zh) 作为pd1/pd-l1抑制剂的化合物及其方法
KR20230158659A (ko) Ctla-4 소분자 분해제 및 그 응용
TW202330519A (zh) 作為ｔａｍ抑制劑的吡唑并吡啶化合物
EA052540B1 (ru) Ингибиторы альфа-диацилглицеринкиназы (дгк) и способы их применения
HK40117800A (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
CN120712269A (zh) Fgfr2和fgfr3的抑制剂及其用途